Whitefort Capital Management, LP 13D and 13G filings for Arbutus Biopharma Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-05-17 09:03 am Unchanged | 2024-05-17 | 13D | Arbutus Biopharma Corporation ABUS | Whitefort Capital Management, LP | 12,867,967 6.800% | 0 (Unchanged) | Filing |
| 2024-05-09 08:00 am Sale | 2024-05-02 | 13D | Arbutus Biopharma Corporation ABUS | Whitefort Capital Management, LP | 12,867,967 6.800% | -329,095 (-2.49%) | Filing |
| 2024-02-14 4:38 pm Purchase | 2023-12-31 | 13G | Arbutus Biopharma Corporation ABUS | Whitefort Capital Management, LP | 13,197,062 7.900% | 3,183,163 (+31.79%) | Filing |
| 2023-09-11 5:07 pm Purchase | 2023-09-01 | 13G | Arbutus Biopharma Corporation ABUS | Whitefort Capital Management, LP | 10,013,899 6.000% | 10,013,899 (New Position) | Filing |